Drug-Coated Balloon Catheters

Global Drug-Coated Balloon Catheters Market to Reach US$2.1 Billion by 2030

The global market for Drug-Coated Balloon Catheters estimated at US$1.5 Billion in the year 2024, is expected to reach US$2.1 Billion by 2030, growing at a CAGR of 6.0% over the analysis period 2024-2030. Paclitaxel, one of the segments analyzed in the report, is expected to record a 4.9% CAGR and reach US$1.3 Billion by the end of the analysis period. Growth in the Sirolimus segment is estimated at 8.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$395.8 Million While China is Forecast to Grow at 9.2% CAGR

The Drug-Coated Balloon Catheters market in the U.S. is estimated at US$395.8 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$414.9 Million by the year 2030 trailing a CAGR of 9.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.0% and 5.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.9% CAGR.

Global "Drug-Coated Balloon Catheter" Market – Key Trends & Drivers Summarized

Why Are Drug-Coated Balloon Catheters Gaining Traction in Cardiovascular Care?

Drug-coated balloon (DCB) catheters have become a game-changer in interventional cardiology and vascular surgery. Unlike traditional stents, DCBs deliver antiproliferative drugs directly to vessel walls, reducing the risk of restenosis without leaving a permanent implant. These devices are particularly useful for coronary artery disease, peripheral artery disease (PAD), and in-stent restenosis, offering a safer alternative with fewer complications.

What Technological Advances Are Improving DCB Performance?

Breakthroughs in polymer-free drug coatings, hydrophilic delivery systems, and biodegradable carriers have enhanced drug retention and absorption in target arteries. The development of paclitaxel-based and sirolimus-coated DCBs has led to longer-lasting therapeutic effects with minimal side effects. Advances in catheter flexibility, precision drug dosing, and imaging-guided deployment have further improved procedural outcomes.

How Are Regulations and Market Demand Influencing Adoption?

Regulatory bodies like the FDA and CE Marking agencies are increasingly approving DCBs for new indications beyond cardiovascular interventions, expanding their use in diabetic vascular complications and arteriovenous fistula treatments. The rise in minimally invasive surgeries and outpatient procedures has also driven demand for DCBs as a cost-effective and efficient alternative to drug-eluting stents (DES).

What Is Propelling the Market Growth?

The growth in the Drug-Coated Balloon Catheter market is fueled by the rising prevalence of cardiovascular diseases, increasing preference for non-stent-based interventions, and advancements in drug delivery coatings. The aging population, growing adoption of outpatient angioplasty procedures, and ongoing clinical trials for new drug formulations are also key market drivers. Furthermore, the expansion of DCB applications into non-cardiac vascular treatments is broadening their clinical relevance and commercial potential.

SCOPE OF STUDY:

The report analyzes the Drug-Coated Balloon Catheters market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Type (Paclitaxel, Sirolimus); Product (Coronary Artery Disease, Peripheral Vascular Disease); End-Use (Hospital, Clinics, Ambulatory Surgery Centers)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 48 Featured) -

• Abbott Laboratories
• Alvimedica
• B. Braun Melsungen AG
• Biotronik SE & Co. KG
• Boston Scientific Corporation
• BD (Becton, Dickinson and Company)
• Cardionovum GmbH
• Concept Medical Inc.
• Eurocor GmbH
• iVascular S.L.U.
• Koninklijke Philips N.V.
• Lepu Medical Technology Co., Ltd.
• Medtronic plc
• Merit Medical Systems, Inc.
• OrbusNeich Medical Group
• QT Vascular Ltd.
• Shockwave Medical, Inc.
• Surmodics, Inc.
• Terumo Corporation
• TriReme Medical, LLC

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.